507 related articles for article (PubMed ID: 24766647)
1. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells.
Ekström EJ; Bergenfelz C; von Bülow V; Serifler F; Carlemalm E; Jönsson G; Andersson T; Leandersson K
Mol Cancer; 2014 Apr; 13():88. PubMed ID: 24766647
[TBL] [Abstract][Full Text] [Related]
2. Wnt5A activates the calpain-mediated cleavage of filamin A.
O'Connell MP; Fiori JL; Baugher KM; Indig FE; French AD; Camilli TC; Frank BP; Earley R; Hoek KS; Hasskamp JH; Elias EG; Taub DD; Bernier M; Weeraratna AT
J Invest Dermatol; 2009 Jul; 129(7):1782-9. PubMed ID: 19177143
[TBL] [Abstract][Full Text] [Related]
3. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2.
Masckauchán TN; Agalliu D; Vorontchikhina M; Ahn A; Parmalee NL; Li CM; Khoo A; Tycko B; Brown AM; Kitajewski J
Mol Biol Cell; 2006 Dec; 17(12):5163-72. PubMed ID: 17035633
[TBL] [Abstract][Full Text] [Related]
4. Migration and invasion of oral squamous carcinoma cells is promoted by WNT5A, a regulator of cancer progression.
Prgomet Z; Axelsson L; Lindberg P; Andersson T
J Oral Pathol Med; 2015 Nov; 44(10):776-84. PubMed ID: 25459554
[TBL] [Abstract][Full Text] [Related]
5. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Anastas JN; Kulikauskas RM; Tamir T; Rizos H; Long GV; von Euw EM; Yang PT; Chen HW; Haydu L; Toroni RA; Lucero OM; Chien AJ; Moon RT
J Clin Invest; 2014 Jul; 124(7):2877-90. PubMed ID: 24865425
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 drives melanoma cell motility through p38α-MAPK-dependent up-regulation of WNT5A expression.
Linnskog R; Jönsson G; Axelsson L; Prasad CP; Andersson T
Mol Oncol; 2014 Dec; 8(8):1365-78. PubMed ID: 24954857
[TBL] [Abstract][Full Text] [Related]
7. Phenylmethimazole decreases Toll-like receptor 3 and noncanonical Wnt5a expression in pancreatic cancer and melanoma together with tumor cell growth and migration.
Schwartz AL; Malgor R; Dickerson E; Weeraratna AT; Slominski A; Wortsman J; Harii N; Kohn AD; Moon RT; Schwartz FL; Goetz DJ; Kohn LD; McCall KD
Clin Cancer Res; 2009 Jun; 15(12):4114-22. PubMed ID: 19470740
[TBL] [Abstract][Full Text] [Related]
8. WNT5A expression increases during melanoma progression and correlates with outcome.
Da Forno PD; Pringle JH; Hutchinson P; Osborn J; Huang Q; Potter L; Hancox RA; Fletcher A; Saldanha GS
Clin Cancer Res; 2008 Sep; 14(18):5825-32. PubMed ID: 18794093
[TBL] [Abstract][Full Text] [Related]
9. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition.
Dissanayake SK; Wade M; Johnson CE; O'Connell MP; Leotlela PD; French AD; Shah KV; Hewitt KJ; Rosenthal DT; Indig FE; Jiang Y; Nickoloff BJ; Taub DD; Trent JM; Moon RT; Bittner M; Weeraratna AT
J Biol Chem; 2007 Jun; 282(23):17259-71. PubMed ID: 17426020
[TBL] [Abstract][Full Text] [Related]
10. Regulation of prostate cancer cell migration toward bone marrow stromal cell-conditioned medium by Wnt5a signaling.
Jin F; Qu X; Fan Q; Wang L; Tang T; Hao Y; Dai K
Mol Med Rep; 2013 Nov; 8(5):1486-92. PubMed ID: 24064566
[TBL] [Abstract][Full Text] [Related]
11. Wnt5a induces endothelial inflammation via beta-catenin-independent signaling.
Kim J; Kim J; Kim DW; Ha Y; Ihm MH; Kim H; Song K; Lee I
J Immunol; 2010 Jul; 185(2):1274-82. PubMed ID: 20554957
[TBL] [Abstract][Full Text] [Related]
12. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma.
O'Connell MP; Fiori JL; Xu M; Carter AD; Frank BP; Camilli TC; French AD; Dissanayake SK; Indig FE; Bernier M; Taub DD; Hewitt SM; Weeraratna AT
Oncogene; 2010 Jan; 29(1):34-44. PubMed ID: 19802008
[TBL] [Abstract][Full Text] [Related]
13. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
14. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma.
Weeraratna AT; Jiang Y; Hostetter G; Rosenblatt K; Duray P; Bittner M; Trent JM
Cancer Cell; 2002 Apr; 1(3):279-88. PubMed ID: 12086864
[TBL] [Abstract][Full Text] [Related]
15. Wnt5a promotes ewing sarcoma cell migration through upregulating CXCR4 expression.
Jin Z; Zhao C; Han X; Han Y
BMC Cancer; 2012 Oct; 12():480. PubMed ID: 23075330
[TBL] [Abstract][Full Text] [Related]
16. Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer.
Zheng H; Chen C; Luo Y; Yu M; He W; An M; Gao B; Kong Y; Ya Y; Lin Y; Li Y; Xie K; Huang J; Lin T
Clin Transl Med; 2021 Jul; 11(7):e497. PubMed ID: 34323412
[TBL] [Abstract][Full Text] [Related]
17. A t-butyloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion.
Jenei V; Sherwood V; Howlin J; Linnskog R; Säfholm A; Axelsson L; Andersson T
Proc Natl Acad Sci U S A; 2009 Nov; 106(46):19473-8. PubMed ID: 19901340
[TBL] [Abstract][Full Text] [Related]
18. Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells.
O'Connell MP; Fiori JL; Kershner EK; Frank BP; Indig FE; Taub DD; Hoek KS; Weeraratna AT
J Biol Chem; 2009 Oct; 284(42):28704-12. PubMed ID: 19696445
[TBL] [Abstract][Full Text] [Related]
19. Methylation and loss of Secreted Frizzled-Related Protein 3 enhances melanoma cell migration and invasion.
Ekström EJ; Sherwood V; Andersson T
PLoS One; 2011 Apr; 6(4):e18674. PubMed ID: 21494614
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy targeting the elevated interleukin-6 level reduces invasive migration of BRAF inhibitor-resistant melanoma cells.
Mohapatra P; Prasad CP; Andersson T
Mol Oncol; 2019 Feb; 13(2):480-494. PubMed ID: 30582770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
